New Website and Roadshow "May" Make for Huge Month for This Biotech
LAS VEGAS, NV / ACCESSWIRE / May 3, 2016 / As public companies attempt to attract long term capital to facilitate their growth it is important that every part of their presentation represents the company in the best possible light. The fact of the matter is, when you're considering investing large amounts of capital into a company, you want to feel comfortable that your money is in good hands.
One part of this process many public companies overlook is their website. If your website looks like it was designed in 1998, it doesn't exactly inspire confidence in investors. One company who gets this is Propanc Health Group Corporation (PPCH).
The company just completed a new website, www.propanc.com, incorporating important new features designed to enhance the experience of the both investors and the broader public keen to understand the Company's technology, its current operations and most importantly, its vision for the future and how it relates to the field of cancer.
In particular, the Investor Relations section of the new website features immediate posting of the Company's press releases as they are issued, as well as the automated posting of SEC filings, XBRL data, Insider Section 16 filings and detailed annual as well as quarterly financial statements. Stock information data such as quotes, charts and historical prices are updated on demand with a 20-minute delay. There is also an IR calendar featuring upcoming events and media coverage as well as an up-to-date frequently asked questions section.
Now if all PPCH had was a new website and a dream, obviously it wouldn't be a big deal. But, this company is fast tracking its PRP treatment, an oncology product initially for targeting pancreatic and ovarian cancers, followed by colorectal cancer, which as a combined world market is expected to reach over $12 billion by 2020.
Propanc's past 12 months in particular has been a whirlwind for investors.
One year ago, the stock sat at the same price just above 3 cents, and from there ran to a high of 13 cents! If not for the biotech selloff in the second half of 2015, PPCH may be at 20 cents or higher by now. However, this selloff has created an opportunity for investors, which many are taking advantage of, the stock traded over 100 million shares in the final week of April. However, this month "May" just be when investors begin to see massive gains.
Keep in mind PPCH began an Institutional Investor Road Show this past Thursday which could yield some large news if the company nets even more favorable financing like it did this past year. PPCH has used its current $4 million dollar financing to discover several other patent opportunities as well as conduct several successful animal studies, leading the company to the brink of human trials for its PRP treatment.
The timing appears to be ripe for investors on PPCH.
A few other biotechs you may want to look at to finish the spring strong include: uniQure N.V.(QURE), Array BioPharma Inc. (ARRY), Ironwood Pharmaceuticals, Inc. (IRWD), Sangamo Biosciences, Inc. (SGMO), Raptor Pharmaceuticals Corp. (RPTP), and Chimerix, Inc. (CMRX).
However, if you're looking for the largest speculative-potential upside, I'd concentrate on PPCH and with the release of their new website coinciding with the Institutional Investor Roadshow the timing could not be better.
LAS VEGAS, NV / ACCESSWIRE / May 3, 2016 / As public companies attempt to attract long term capital to facilitate their growth it is important that every part of their presentation represents the company in the best possible light. The fact of the matter is, when you're considering investing large amounts of capital into a company, you want to feel comfortable that your money is in good hands.
One part of this process many public companies overlook is their website. If your website looks like it was designed in 1998, it doesn't exactly inspire confidence in investors. One company who gets this is Propanc Health Group Corporation (PPCH).
The company just completed a new website, www.propanc.com, incorporating important new features designed to enhance the experience of the both investors and the broader public keen to understand the Company's technology, its current operations and most importantly, its vision for the future and how it relates to the field of cancer.
In particular, the Investor Relations section of the new website features immediate posting of the Company's press releases as they are issued, as well as the automated posting of SEC filings, XBRL data, Insider Section 16 filings and detailed annual as well as quarterly financial statements. Stock information data such as quotes, charts and historical prices are updated on demand with a 20-minute delay. There is also an IR calendar featuring upcoming events and media coverage as well as an up-to-date frequently asked questions section.
Now if all PPCH had was a new website and a dream, obviously it wouldn't be a big deal. But, this company is fast tracking its PRP treatment, an oncology product initially for targeting pancreatic and ovarian cancers, followed by colorectal cancer, which as a combined world market is expected to reach over $12 billion by 2020.
Propanc's past 12 months in particular has been a whirlwind for investors.
One year ago, the stock sat at the same price just above 3 cents, and from there ran to a high of 13 cents! If not for the biotech selloff in the second half of 2015, PPCH may be at 20 cents or higher by now. However, this selloff has created an opportunity for investors, which many are taking advantage of, the stock traded over 100 million shares in the final week of April. However, this month "May" just be when investors begin to see massive gains.
Keep in mind PPCH began an Institutional Investor Road Show this past Thursday which could yield some large news if the company nets even more favorable financing like it did this past year. PPCH has used its current $4 million dollar financing to discover several other patent opportunities as well as conduct several successful animal studies, leading the company to the brink of human trials for its PRP treatment.
The timing appears to be ripe for investors on PPCH.
A few other biotechs you may want to look at to finish the spring strong include: uniQure N.V.(QURE), Array BioPharma Inc. (ARRY), Ironwood Pharmaceuticals, Inc. (IRWD), Sangamo Biosciences, Inc. (SGMO), Raptor Pharmaceuticals Corp. (RPTP), and Chimerix, Inc. (CMRX).
However, if you're looking for the largest speculative-potential upside, I'd concentrate on PPCH and with the release of their new website coinciding with the Institutional Investor Roadshow the timing could not be better.
